instagram.com/ @thesikhtimes facebook.com/ thesikhtimes qaumipatrika VISIT: PUBLISHED FROM Delhi, Haryana, Uttar www.thesikhtimes.in Pradesh, Punjab, The Sikh Times Email:
[email protected] Chandigarh, Himachal and Jammu National Daily Vol. 12 No. 223 RNI NO. DELENG/2008/25465 New Delhi, Saturday, 2 January, 2021
[email protected] 9971359517 12 pages. 2/- Simmi Kaur Babbar ÁŒÀ‹Ë ∑‘§ ’ÊÚ«¸⁄UÙ¥ ¬⁄U ’ÒΔ ‹ÊπÙ¥ Á∑§‚ÊŸÙ¥ ∑‘§ ‚ÊÕ ∑§Ù߸ ŸÃÊ ÿÊ ‚⁄U∑§Ê⁄U œÙπÊ Ÿ„Ë¥ Oxford-AstraZeneca Covid vaccine set to become first to get approval in India New Delhi, January 1: An expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) is set to recom- mend granting emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India, sources said on Friday.The Pune-based Serum ∑§⁄U ‚∑§ÃË– Institute of India (SII), the world’s largest vac- cine manufacturer, has tied up with AstraZeneca to manufacture Covishield. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday had approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use.The Subject Á∑§‚ÊŸÙ¥ ‚ ªgÊ⁄UË ∑§⁄UŸ flÊ‹Ê Expert Committee (SEC) on COVID-19 of the CDSCO, which had earlier sought additional safety and immunogenicity data from SII, delib- erated on its application seeking emergency use authorisation (EUA) for the shots on Wednesday, and met again on Friday to review ’ŇÊÊ Ÿ„Ë¥ ¡Ê∞ªÊ– the matter. After SII’s application, the SEC has started reviewing the EUA application by Bharat Biotech for its COVID-19 vaccine Covaxin but is yet to take a final decision on the Gurcharan Singh Babbar matter, sources said.